Göller Bulut Duygu, Bayrak Seval, Uyeturk Ummügül, Ankarali Handan
1 Department of Dentomaxillofacial Radiology, Abant Izzet Baysal University, Faculty of Dentistry , Bolu , Turkey.
2 Department of Medical Oncology, Abant Izzet Baysal University, Faculty of Medicine , Bolu , Turkey.
Br J Radiol. 2018 Nov;91(1091):20180442. doi: 10.1259/bjr.20180442. Epub 2018 Jul 18.
: This study was conducted to evaluate fractal dimension (FD), mandibular cortical width (MCW), panoramic mandibular index (PMI), and mandibular cortical index (MCI) on panoramic radiographs to determine the mandibular cortical and trabecular bone changes in females with breast cancer undergoing aromatase inhibitors (AIs) treatment.
: In this retrospective study, FD analysis, PMI, MCI, and MCW were assessed over panoramic radiographs of 34 females under AI therapy as a patient group and 34 healthy age-gender matched individuals as a control group.
: Mean FD values and MCW were slightly but not significantly lower in the patient group (1.47 ± 0.06 and 4.1 ± 1.2 respectively). FDs measured onthe supracortical area above the angulus mandibula (FD2) and anterior to the mental foramen (FD4) were significantly lower in patients (p = 0.037 and p = 0.046 respectively). Among the measured regions in patients, FD2 was significantly lower (p = 0.001). PMI was also significantly lower in patients (p = 0.001) and MCI were similar in both groups (p = 0.604).
: AI use affects bone quality and evaluating FD, PMI, and MCW in panoramic radiography can be used to determine the effect of this drug on the jaw bones in the early period.
: Aromatase inhibitors are the most commonly used drugs in breast cancer patients. This drug is thought to have osteoporotic effects on the jawbone. This study is the first study to evaluate osteoporotic changes with measurements made on panoramic radiographs and the results of the study are significant. We think this study will shed light on the studies that will investigate the effects of the drug on the jaw bones.
本研究旨在评估全景X线片上的分形维数(FD)、下颌骨皮质宽度(MCW)、全景下颌指数(PMI)和下颌骨皮质指数(MCI),以确定接受芳香化酶抑制剂(AIs)治疗的乳腺癌女性患者下颌骨皮质和小梁骨的变化。
在这项回顾性研究中,对34名接受AI治疗的女性患者组和34名年龄、性别匹配的健康个体作为对照组的全景X线片进行FD分析、PMI、MCI和MCW评估。
患者组的平均FD值和MCW略低,但无显著差异(分别为1.47±0.06和4.1±1.2)。在下颌角上方的皮质上区域(FD2)和颏孔前方(FD4)测量的FD值在患者中显著较低(分别为p = 0.037和p = 0.046)。在患者测量的区域中,FD2显著较低(p = 0.001)。患者的PMI也显著较低(p = 0.001),两组的MCI相似(p = 0.604)。
使用AI会影响骨质量,在全景X线摄影中评估FD、PMI和MCW可用于早期确定该药物对颌骨的影响。
芳香化酶抑制剂是乳腺癌患者最常用的药物。该药物被认为对颌骨有骨质疏松作用。本研究是第一项通过全景X线片测量评估骨质疏松变化的研究,研究结果具有重要意义。我们认为这项研究将为调查该药物对颌骨影响的研究提供启示。